Pentobarbital therapy for intracranial hypertension in metabolic coma. Reye's syndrome.
In severe Reye's syndrome, with nonspecific intensive supportive therapy, the mortality rate approaches 75%. In many instances, death is due to uncontrolled cerebral edema and elevated intracranial pressure. (ICP). Pentobarbital therapy, sufficient to maintain a blood barbiturate level between 2.5 mg% and 4.0 mg%, was used to control ICP in seven patients with metabolic coma complicated by intracranial hypertension (intracranial pressure greater than 30 mm Hg for 30 min). The nadir of their neurological function was characterized by no response to deep pain, absent or abnormal oculocephalic responses, bilaterally dilated, unreactive pupils, and markedly irregular or absent respirations. Before barbiturate administration hyperventilation, steroids, mannitol, and other supportive therapies commonly used in Reye's syndrome were begun. After institution of pentobarbital therapy, the daily mannitol dose required to maintain the intracranial pressure below 20 mm Hg was significantly reduced (p less than 0.001), from 3.7 +/- 0.3 to 0.5 +/- 0.2 g/kg/day. All the patients survived, and six have no obvious neurological sequelae. Pentobarbital is a useful adjunct for intracranial pressure control in advanced metabolic coma.
D000293:Adolescent; D001463:Barbiturates / Q000097:blood; D001929:Brain Edema / Q000188:drug therapy*; D003422:Critical Care; D005260:Female; D006801:Humans; D007427:Intracranial Pressure / Q000187:drug effects; D008353:Mannitol / Q000008:administration & dosage; D010424:Pentobarbital / Q000627:therapeutic use*; D012202:Reye Syndrome / Q000150:complications* / Q000401:mortality
D001463:Barbiturates; D008353:Mannitol; D010424:Pentobarbital